{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T09:41:20Z","timestamp":1788428480185,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypophosphatasia (HPP) is a rare, inherited, systemic disease characterized by skeletal and systemic manifestations. Asfotase alfa (AA) is the only US Food and Drug Administration-approved treatment for perinatal\/infantile- and juvenile-onset HPP. Real-world data are scarce on fracture rates and healthcare resource utilization (HCRU) in patients treated with AA. This retrospective, observational study evaluated fracture-related outcomes and HCRU in patients with HPP treated with AA from January 2016 to December 2022 using the US Medicare Fee-for-Service and Inovalon Medical Outcomes Research for Effectiveness and Economics closed claims databases. Patients (\u22652\u00a0yr of age) treated with AA (\u22651 pharmacy claim for AA between January 2017 and December 2021 [identification period]) and \u226512\u00a0mo of continuous enrollment with medical and pharmacy coverage pre- and post-AA initiation were included. Clinical outcomes (change in fractures, types of fractures, and fracture event rates) and HCRU were assessed. Statistical analyses were performed to compare outcomes before and after initiation of AA. One hundred forty-nine patients (65.1% females, 69.1% adults; mean age, 39.6\u00a0yr) met the inclusion criteria. The proportion of patients experiencing fractures in the 12\u00a0mo following AA initiation significantly decreased compared to the 12\u00a0mo prior to treatment (18.1% vs 8.1%; p\u2009=\u2009.004). The mean fracture rate per patient per year nominally decreased post-AA initiation (0.24 vs 0.14; p\u2009=\u2009.096). The decrease was significant in fragility fracture rates (0.08 vs 0.02; p\u2009=\u2009.019). Most prescribed concomitant drugs at baseline were opioid analgesics (36.9%), nonopioid analgesics (34.2%), and antidepressants (34.9%). At baseline, 38.2% of patients were continuously using opioids and 21.8% were using high-dose opioids. Asfotase alfa initiation was associated with a statistically significant reduction in the proportion of patients experiencing fractures and fragility fracture rates, underscoring its potential therapeutic benefits.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf188","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:09:03Z","timestamp":1765285743000},"source":"Crossref","is-referenced-by-count":1,"title":["Change in fracture rate and healthcare resource utilization among patients with hypophosphatasia following initiation of asfotase alfa: a retrospective US claims database analysis"],"prefix":"10.1093","volume":"10","author":[{"given":"Genevieve","family":"Lyons","sequence":"first","affiliation":[{"name":"Health Economics and Outcomes Research and Medical Affairs, Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Bates","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research and Medical Affairs, Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Vlasnik","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research and Medical Affairs, Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Wakeford","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research and Medical Affairs, Alexion, AstraZeneca Rare Disease , Boston, MA 02210 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A","family":"Donckels","sequence":"additional","affiliation":[{"name":"Insights, Inovalon , Bowie, MD 20716 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip K","family":"Chan","sequence":"additional","affiliation":[{"name":"Insights, Inovalon , Bowie, MD 20716 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott B","family":"Robinson","sequence":"additional","affiliation":[{"name":"Insights, Inovalon , Bowie, MD 20716 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-9138","authenticated-orcid":false,"given":"Kathryn M","family":"Dahir","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Vanderbilt University Medical Center , Nashville, TN 37232 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"3","key":"2026011009470214900_ref1","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s00198-023-06844-1","article-title":"Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults","volume":"35","author":"Khan","year":"2024","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026011009470214900_ref2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12891-019-2420-8","article-title":"Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry","volume":"20","author":"H\u00f6gler","year":"2019","journal-title":"BMC Musculoskelet Disord"},{"key":"2026011009470214900_ref3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2019.01.049","article-title":"Natural history of perinatal and infantile hypophosphatasia: a retrospective study","volume":"209","author":"Whyte","year":"2019","journal-title":"J Pediatr"},{"key":"2026011009470214900_ref4","doi-asserted-by":"publisher","first-page":"115795","DOI":"10.1016\/j.bone.2020.115795","article-title":"Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic","volume":"144","author":"Desborough","year":"2021","journal-title":"Bone"},{"issue":"3","key":"2026011009470214900_ref5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-016-0309-0","article-title":"Hypophosphatasia","volume":"14","author":"Linglart","year":"2016","journal-title":"Curr Osteoporos Rep"},{"issue":"8","key":"2026011009470214900_ref6","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00198-020-05345-9","article-title":"Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment","volume":"31","author":"Bianchi","year":"2020","journal-title":"Osteoporos Int"},{"issue":"10","key":"2026011009470214900_ref7","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/jcph.1870","article-title":"Pharmacokinetics of asfotase alfa in adult patients with pediatric-onset hypophosphatasia","volume":"61","author":"Pan","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2026011009470214900_ref8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/jbmr.3075","article-title":"Hypophosphatasia: enzyme replacement therapy brings new opportunities and new challenges","volume":"32","author":"Whyte","year":"2017","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026011009470214900_ref9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40259-016-0161-x","article-title":"Asfotase alfa in perinatal\/infantile-onset and juvenile-onset hypophosphatasia: a guide to its use in the USA","volume":"30","author":"Scott","year":"2016","journal-title":"BioDrugs"},{"issue":"7","key":"2026011009470214900_ref10","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","article-title":"Efficacy and safety of asfotase alfa in infants and young children with hypophosphatasia: a phase 2 open-label study","volume":"104","author":"Hofmann","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026011009470214900_ref11","doi-asserted-by":"publisher","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","article-title":"Asfotase alfa therapy for children with hypophosphatasia","volume":"1","author":"Whyte","year":"2016","journal-title":"JCI Insight"},{"issue":"10","key":"2026011009470214900_ref12","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","article-title":"Enzyme-replacement therapy in life-threatening hypophosphatasia","volume":"366","author":"Whyte","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2026011009470214900_ref13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/s2213-8587(18)30307-3","article-title":"Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial","volume":"7","author":"Whyte","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2026011009470214900_ref14","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1210\/jc.2015-3462","article-title":"Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia","volume":"101","author":"Whyte","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2026011009470214900_ref15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.bone.2018.12.011","article-title":"Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia","volume":"121","author":"Kishnani","year":"2019","journal-title":"Bone"},{"issue":"5","key":"2026011009470214900_ref16","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/jbm4.10052","article-title":"Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy","volume":"2","author":"Klidaras","year":"2018","journal-title":"JBMR Plus"},{"key":"2026011009470214900_ref17","doi-asserted-by":"publisher","first-page":"115794","DOI":"10.1016\/j.bone.2020.115794","article-title":"Bone healing and reactivation of remodeling under asfotase alfa therapy in adult patients with pediatric-onset hypophosphatasia","volume":"143","author":"St\u00fcrznickel","year":"2021","journal-title":"Bone"},{"issue":"8","key":"2026011009470214900_ref18","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00198-018-4552-3","article-title":"Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia\u2013not atypical at all","volume":"29","author":"Genest","year":"2018","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026011009470214900_ref19","doi-asserted-by":"publisher","first-page":"5583096","DOI":"10.1155\/crie\/5583096","article-title":"Improvements in bone disorganization and pseudo-fracture healing in hypophosphatasia following asfotase alfa therapy may be detectable by the ALIGNOGRAM before changes in bone radiography or scintigraphy","volume":"2025","author":"Zebaze","year":"2025","journal-title":"Case Rep Endocrinol"},{"issue":"1","key":"2026011009470214900_ref20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13023-018-0869-4","article-title":"Healthcare resource utilization in the management of hypophosphatasia in three patients displaying a spectrum of manifestations","volume":"13","author":"Daniel","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"2026011009470214900_ref21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36469\/001c.87538","article-title":"Use of open claims vs closed claims in health outcomes research","volume":"10","author":"Baser","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"key":"2026011009470214900_ref22","author":"U.S. Dept. of Health & Human Services","year":"2024"},{"issue":"5","key":"2026011009470214900_ref23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"3","key":"2026011009470214900_ref24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","article-title":"CDC clinical practice guideline for prescribing opioids for pain\u2014United States, 2022","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"issue":"1","key":"2026011009470214900_ref25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13023-022-02393-8","article-title":"Clinical profiles of treated and untreated adults with hypophosphatasia in the Global HPP Registry","volume":"17","author":"Dahir","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"2026011009470214900_ref26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and exogenous opioids in pain","volume":"41","author":"Corder","year":"2018","journal-title":"Annu Rev Neurosci"},{"key":"2026011009470214900_ref27","doi-asserted-by":"publisher","first-page":"1138599","DOI":"10.3389\/fendo.2023.1138599","article-title":"Impact of muscular symptoms and\/or pain on disease characteristics, disability, and quality of life in adult patients with hypophosphatasia: a cross-sectional analysis from the Global HPP Registry","volume":"14","author":"Dahir","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026011009470214900_ref28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00198-020-05612-9","article-title":"Bone mineral density and fracture risk in adult patients with hypophosphatasia","volume":"32","author":"Genest","year":"2021","journal-title":"Osteoporos Int"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf188\/65828302\/ziaf188.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/1\/ziaf188\/65828302\/ziaf188.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/10\/1\/ziaf188\/65828302\/ziaf188.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T14:47:09Z","timestamp":1768056429000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf188\/8376515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf188","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,10]]},"article-number":"ziaf188"}}